The FDA approved Zioptan (tafluprost ophthalmic solution) to help reduce elevated eye pressure in people with open-angle glaucoma. The drug is also approved for use in patients with higher-than-normal eye pressure (ocular hypertension), an important risk factor for glaucoma, the second leading cause of blindness in the United States. Patients with ocular hypertension frequently are considered to have a greater chance of developing glaucoma.
“Zioptan’s approval provides an alternative treatment option for patients living with this potentially blinding disease,” said Edward Cox, M.D., M.P.H, director of the Office of Antimicrobial Products in FDA’s Center for Drug Evaluation and Research.
Zioptan is an eye drop that should be used once daily in the evening. In clinical studies up to 24 months in duration, patients with open-angle glaucoma or ocular hypertension treated with Zioptan in the evening showed reduced eye pressure at three and six months.
People using Zioptan may see darkening of the iris, which may be permanent, and darkening of the eyelid, which may be reversible. Those using the drug also experience eyelash growth.
Zioptan is marketed by Whitehouse Station, N.J.-based Merck & Co. Inc.
See the FDA Announcement